Publication Name	World Journal of Clinical Cases
Manuscript ID	68776
Country	China

Received	2021-06-04 01:37
Peer-Review Started	2021-06-04 01:40
To Make the First Decision
Return for Revision	2021-09-01 10:15
Revised	2021-09-26 10:44
Second Decision	2022-03-04 05:58
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-03-06 22:10
Articles in Press	2022-03-06 22:10
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-03-02 01:19
Typeset the Manuscript	2022-03-20 01:55
Publish the Manuscript Online	2022-04-21 11:35

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Case Report
Article Title	Anti-programmed death 1 antibody in the treatment of coexistent Mycobacterium fortuitum and lung cancer: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Cui-Cui Zhang and Peng Chen
ORCID	Author(s) ORCID Number Cui-Cui Zhang http://orcid.org/0000-0002-3187-9324 Peng Chen http://orcid.org/0000-0003-3153-7591
Funding Agency and Grant Number
Corresponding Author	Peng Chen, MD, Chief Doctor, Professor, Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, West Huanhu Rd, Tianjin 300060, China. pengchentj@126.com
Key Words	Mycobacterium fortuitum; Nontuberculous mycobacterium; Non-small cell lung cancer; Immune checkpoint inhibitors; Case report
Core Tip	The clinical experience in the application of immune checkpoint inhibitors is scarce for lung cancer patients with pulmonary tuberculosis, and lung cancer with nontuberculous mycobacterium (NTM) is even more rare. We present the case of a patient who had both lung cancer and NTM. NTM was stable, and the tumors shrank after treatment with immune checkpoint inhibitors. It provides some reference for the treatment of coexistent lung cancer with NTM.
Publish Date	2022-04-21 11:35
Citation	Zhang CC, Chen P. Anti-programmed death 1 antibody in the treatment of coexistent Mycobacterium fortuitum and lung cancer: A case report. World J Clin Cases 2022; 10(12): 3801-3807
URL	https://www.wjgnet.com/2307-8960/full/v10/i12/3801.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i12.3801

Full Article (PDF)	WJCC-10-3801.pdf
Full Article (Word)	WJCC-10-3801.docx
Manuscript File	68776_Auto_Edited-YJM-FilipodiaCL.docx
Answering Reviewers	68776-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	68776-Conflict-of-interest statement.pdf
Copyright License Agreement	68776-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	68776-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	68776-Language certificate.pdf
Peer-review Report	68776-Peer-review(s).pdf
Scientific Editor Work List	68776-Scientific editor work list.pdf
CrossCheck Report	68776-CrossCheck report.pdf